Biological
MASCT-I
MASCT-I is a biological therapy with 4 clinical trials. Currently 1 active trials ongoing.
Total Trials
4
Max Phase
—
Type
BIOLOGICAL
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(25%)
Terminated
1(25%)
Phase Distribution
Ph phase_1
3
75%
Ph phase_2
1
25%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Terminated(1)
Other(2)
Detailed Status
unknown2
Recruiting1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
0.0%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
recruiting125%
unknown250%
terminated125%
Recent Activity
1 active trials
Showing 4 of 4
terminatedphase_1
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
NCT03034304
recruitingphase_2
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
NCT06277154
unknownphase_1
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
NCT03393416
unknownphase_1
MASCT-I Treatment for Advanced Solid Tumor
NCT02858232
Clinical Trials (4)
Showing 4 of 4 trials
NCT03034304Phase 1
A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors
NCT06277154Phase 2
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
NCT03393416Phase 1
A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
NCT02858232Phase 1
MASCT-I Treatment for Advanced Solid Tumor
All 4 trials loaded
Drug Details
- Intervention Type
- BIOLOGICAL
- Total Trials
- 4